Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Aurora Cannabis Inc.NASDAQ: ACB

Net Change in Cash · Q4 FY2026 · quarter ended Mar 2026

Net change in cash declines year over year

Q4 FY2026 net change in cash of CA$8.83M fell 69.8% year over year, ahead of the -396.2% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -21.9% a year.

Context

  • Net change in cash amounted to 20.8% of revenue in FY2026, up 20.3 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -69.8% holds above the trailing-twelve-month pace of -396.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$8.83M+122.5% QoQ
Last fiscal yearMar 2026
-CA$66.81M-3758.9% YoY
LTMMar 2026
-CA$72.73M-396.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.8%——
1 year-3758.9%——
3-year CAGR-21.9%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

CAD · from the cash flow

Latest · FY2026
(66.81M) CAD
Year-over-year change
-3758.9%

Net Change in Cash vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -396.2% is the lowest of 10, against a peer median of +105.1%.
  • Net change in cash amounts to 23.4% of revenue for ACB, versus a peer median of 15.5%.
ACB Competitors
Net Change in Cash for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$278.14M CAD+592.4%—89.0%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$111.99M USD+957.6%+52.1%31.0%
ACBAurora Cannabis Inc.LTM Mar 2026CA$72.73M CAD-396.2%-21.9%23.4%
OGIOrganigram Global Inc.LTM Mar 2026CA$29.19M CAD+92.5%—10.6%
EDITEditas Medicine, Inc.LTM Mar 2026$16.25M USD-123.4%—42.0%
BIOABioAge Labs, Inc.LTM Mar 2026$15.71M USD-119.6%+70.2%152.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$3.42M USD——2.5%
HITIHigh Tide Inc.LTM Apr 2026CA$1.95M CAD+1180.1%-61.8%0.3%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.7M USD-69.1%—20.3%
TKNOAlpha Teknova, Inc.LTM Mar 2026$929K USD+105.1%—2.2%
LFMDLifeMD, Inc.LTM Mar 2026$84.73K USD+111.8%—0.0%
Peer median (excluding ACB) —+105.1%+52.1%15.5%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(57.08M)15.76M(58.77M)
Depreciation & Amortization93.66M43.57M32.78M22.55M14.23M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55.14K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.54M)10.21M(9.24M)
Accounts Receivables18.34M5.53M(4.5M)5.24M(8.17M)
Inventory21.07M49.03M3.87M(15.05M)65.93M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.06M)
Other Working Capital6.48M(71.61M)790K5.11M(58.93M)
Other Non-Cash Items1.45B190.11M(39.71M)(40.85M)40.18M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.55M)
Capital Expenditures(32.21M)(12.13M)(16.83M)(18.86M)(22.6M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments0000(52.35M)
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K14.02M(956K)235.61K
Investing Cash Flow(36.17M)(27.29M)(3.36M)(14.33M)(73.62M)
Debt Repayment(170.83M)—(85.37M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.92M820K9.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(475K)(131K)(154.4K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.79M
Effect of Forex Changes15.01M15.54M297K264K10.56M
Net Change in Cash16.35M(140.01M)(119.5M)1.83M(66.81M)
Free Cash Flow(142.48M)(127.95M)(85.34M)(2.85M)(36.15M)

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.